AC   CVCL_0530
DR   BTO; BTO:0002914
DR   CLO; CLO_0009058
DR   EFO; EFO_0002860
DR   MCCL; MCC:0000429
DR   CLDB; cl4338
DR   CLDB; cl4339
DR   CLDB; cl4340
DR   CLDB; cl4341
DR   CLDB; cl4342
DR   CLDB; cl4343
DR   ArrayExpress; E-MTAB-2770
DR   BioSample; SAMN01821666
DR   BioSample; SAMN03151999
DR   BioSample; SAMN10987896
DR   CCRID; 1101HUM-PUMC000263
DR   Cell_Model_Passport; SIDM00634
DR   ChEMBL-Cells; CHEMBL3307551
DR   ChEMBL-Targets; CHEMBL614163
DR   CLS; 300340
DR   Cosmic; 753613
DR   Cosmic; 897448
DR   Cosmic; 922655
DR   Cosmic; 1078367
DR   Cosmic; 1078391
DR   Cosmic; 1082511
DR   Cosmic; 1084314
DR   Cosmic; 2228233
DR   Cosmic; 2250468
DR   Cosmic; 2301579
DR   DepMap; ACH-000039
DR   DSMZ; ACC-203
DR   DSMZCellDive; ACC-203
DR   ECACC; 90022302
DR   GEO; GSM393038
DR   GEO; GSM510009
DR   GEO; GSM824868
DR   GEO; GSM824869
DR   GEO; GSM887596
DR   GEO; GSM888679
DR   GEO; GSM945247
DR   GEO; GSM945264
DR   GEO; GSM1022638
DR   GEO; GSM1676318
DR   GEO; GSM1701651
DR   IARC_TP53; 23586
DR   KCB; KCB 2012033YJ
DR   KCLB; 30010
DR   LiGeA; CCLE_596
DR   Lonza; 82
DR   NCBI_Iran; C535
DR   PharmacoDB; SKNMC_1408_2019
DR   Progenetix; CVCL_0530
DR   TOKU-E; 3148
DR   Wikidata; Q54954478
RX   DOI=10.1007/978-1-4757-1647-4_13;
RX   DOI=10.1016/B978-0-12-333530-2.50006-X;
RX   DOI=10.5282/edoc.27750;
RX   PubMed=29704;
RX   PubMed=62055;
RX   PubMed=327080;
RX   PubMed=2784858;
RX   PubMed=2987426;
RX   PubMed=3518877;
RX   PubMed=4748425;
RX   PubMed=6582512;
RX   PubMed=7037175;
RX   PubMed=7459858;
RX   PubMed=7591257;
RX   PubMed=8040301;
RX   PubMed=8378080;
RX   PubMed=8570170;
RX   PubMed=8617485;
RX   PubMed=8665486;
RX   PubMed=9121763;
RX   PubMed=11668190;
RX   PubMed=15390183;
RX   PubMed=18160777;
RX   PubMed=19787792;
RX   PubMed=20143388;
RX   PubMed=22460905;
RX   PubMed=23325432;
RX   PubMed=24312454;
RX   PubMed=25010205;
RX   PubMed=25223734;
RX   PubMed=26351324;
RX   PubMed=26428435;
RX   PubMed=30879952;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
CC   Problematic cell line: Misclassified. Originally thought to be a neuroblastoma cell line but shown to be from an Askin tumor (PubMed=20143388).
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: ENCODE project common cell types; tier 3.
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00267.
CC   Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK 776.
CC   Population: Caucasian.
CC   Doubling time: 32 hours (PubMed=4748425); 23 hours (PubMed=24312454); ~32 hours (CLS); ~48 hours (DSMZ).
CC   Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=7591257; PubMed=8040301; PubMed=25010205).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.170_572del; Zygosity=Unspecified (PubMed=19787792; PubMed=26428435).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: H3K4me3 ChIP-seq epigenome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=1.84%; Native American=0%; East Asian, North=0.61%; East Asian, South=0%; South Asian=0.27%; European, North=67.85%; European, South=29.43% (PubMed=30894373).
CC   Derived from metastatic site: Supra-orbital region.
ST   Source(s): ATCC; CCRID; CLS; COG; DSMZ; KCLB; PubMed=19787792; PubMed=24312454; PubMed=25010205; PubMed=30879952
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 11
ST   D16S539: 12
ST   D18S51: 13,14 (CCRID; CLS; DSMZ; PubMed=24312454; PubMed=25010205)
ST   D18S51: 14 (PubMed=19787792)
ST   D19S433: 13,15.2 (CCRID; PubMed=19787792; PubMed=24312454; PubMed=25010205)
ST   D19S433: 13,16 (DSMZ)
ST   D21S11: 30,31.2 (CLS; COG; DSMZ; PubMed=19787792; PubMed=24312454; PubMed=25010205)
ST   D21S11: 30,31.2,32.2 (CCRID)
ST   D2S1338: 17,21
ST   D3S1358: 15 (CLS; KCLB; PubMed=19787792; PubMed=30879952)
ST   D3S1358: 15,16 (CCRID; DSMZ; PubMed=24312454; PubMed=25010205)
ST   D5S818: 11
ST   D7S820: 8
ST   D8S1179: 10
ST   FGA: 21,25
ST   Penta D: 8,9,13 (DSMZ)
ST   Penta D: 9,13 (CLS)
ST   Penta E: 16,18
ST   SE33: 16
ST   TH01: 9.3
ST   TPOX: 9,11 (ATCC; CCRID; CLS; COG; DSMZ; KCLB; PubMed=24312454; PubMed=25010205; PubMed=30879952)
ST   TPOX: 11 (PubMed=19787792)
ST   vWA: 17,18
DI   NCIt; C7542; Askin tumor
DI   ORDO; Orphanet_370348; Peripheral primitive neuroectodermal tumor
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   12Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 23-06-22; Version: 38
RX   DOI=10.1007/978-1-4757-1647-4_13;
RA   Biedler J.L.;
RT   "Chromosome abnormalities in human tumor cells in culture.";
RL   (In) Human tumor cells in vitro; Fogh J. (eds.); pp.359-394; Springer; New York (1975).
RX   DOI=10.1016/B978-0-12-333530-2.50006-X;
RA   Israel M.A., Thiele C.J.;
RT   "Tumor cell lines of the peripheral nervous system.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.43-78; Academic Press; New York (1994).
RX   DOI=10.5282/edoc.27750;
RA   Orth M.F.;
RT   "Systematic multi-omics profiling of Ewing sarcoma cell lines.";
RL   Thesis PhD (2021), Ludwig Maximilians University of Munich, Germany.
RX   PubMed=29704;
RA   Biedler J.L., Roffler-Tarlov S., Schachner M., Freedman L.S.;
RT   "Multiple neurotransmitter synthesis by human neuroblastoma cell lines
RT   and clones.";
RL   Cancer Res. 38:3751-3757(1978).
RX   PubMed=62055; DOI=10.1093/jnci/57.3.683;
RA   Biedler J.L., Spengler B.A.;
RT   "A novel chromosome abnormality in human neuroblastoma and
RT   antifolate-resistant Chinese hamster cell lives in culture.";
RL   J. Natl. Cancer Inst. 57:683-695(1976).
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
RX   PubMed=2784858; DOI=10.1073/pnas.86.8.2804;
RA   Knuth A., Wolfel T., Klehmann E., Boon T.,
RA   Meyer zum Buschenfelde K.-H.;
RT   "Cytolytic T-cell clones against an autologous human melanoma:
RT   specificity study and definition of three antigens by
RT   immunoselection.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:2804-2808(1989).
RX   PubMed=2987426; DOI=10.1007/BF00165170;
RA   Helson L., Helson C.;
RT   "Human neuroblastoma cells and 13-cis-retinoic acid.";
RL   J. Neurooncol. 3:39-41(1985).
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
RX   PubMed=4748425;
RA   Biedler J.L., Helson L., Spengler B.A.;
RT   "Morphology and growth, tumorigenicity, and cytogenetics of human
RT   neuroblastoma cells in continuous culture.";
RL   Cancer Res. 33:2643-2652(1973).
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
RX   PubMed=7037175;
RA   Reynolds C.P., Reynolds D.A., Frenkel E.P., Smith R.G.;
RT   "Selective toxicity of 6-hydroxydopamine and ascorbate for human
RT   neuroblastoma in vitro: a model for clearing marrow prior to
RT   autologous transplant.";
RL   Cancer Res. 42:1331-1336(1982).
RX   PubMed=7459858;
RA   Rousset M., Zweibaum A., Fogh J.;
RT   "Presence of glycogen and growth-related variations in 58 cultured
RT   human tumor cell lines of various tissue origins.";
RL   Cancer Res. 41:1165-1170(1981).
RX   PubMed=7591257; DOI=10.1002/ijc.2910630407;
RA   Ida K., Kobayashi S., Taki T., Hanada R., Bessho F., Yamamori S.,
RA   Sugimoto T., Ohki M., Hayashi Y.;
RT   "EWS-FLI-1 and EWS-ERG chimeric mRNAs in Ewing's sarcoma and primitive
RT   neuroectodermal tumor.";
RL   Int. J. Cancer 63:500-504(1995).
RX   PubMed=8040301; DOI=10.1172/JCI117360;
RA   Giovannini M., Biegel J.A., Serra M., Wang J.-Y., Wei Y.H., Nycum L.,
RA   Emanuel B.S., Evans G.A.;
RT   "EWS-erg and EWS-Fli1 fusion transcripts in Ewing's sarcoma and
RT   primitive neuroectodermal tumors with variant translocations.";
RL   J. Clin. Invest. 94:489-496(1994).
RX   PubMed=8378080;
RA   Kovar H., Auinger A., Jug G., Aryee D.N.T., Zoubek A.,
RA   Salzer-Kuntschik M., Gadner H.;
RT   "Narrow spectrum of infrequent p53 mutations and absence of MDM2
RT   amplification in Ewing tumours.";
RL   Oncogene 8:2683-2690(1993).
RX   PubMed=8570170;
RA   van Weering D.H.J., Medema J.P., van Puijenbroek A.A.F.L.,
RA   Burgering B.M.T., Baas P.D., Bos J.L.;
RT   "Ret receptor tyrosine kinase activates extracellular signal-regulated
RT   kinase 2 in SK-N-MC cells.";
RL   Oncogene 11:2207-2214(1995).
RX   PubMed=8617485; DOI=10.1016/S0046-8177(96)90115-X;
RA   Scotlandi K., Serra M., Manara M.C., Benini S., Sarti M., Maurici D.,
RA   Lollini P.-L., Picci P., Bertoni F., Baldini N.;
RT   "Immunostaining of the p30/32MIC2 antigen and molecular detection of
RT   EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral
RT   neuroectodermal tumor.";
RL   Hum. Pathol. 27:408-416(1996).
RX   PubMed=8665486; DOI=10.1016/0304-3835(96)04250-4;
RA   Diccianni M.B., Chau L.S., Batova A., Vu T.Q., Yu A.L.-T.;
RT   "The p16 and p18 tumor suppressor genes in neuroblastoma: implications
RT   for drug resistance.";
RL   Cancer Lett. 104:183-192(1996).
RX   PubMed=9121763; DOI=10.1038/sj.onc.1200911;
RA   van Puijenbroek A.A.F.L., van Weering D.H.J., van den Brink C.E.,
RA   Bos J.L., van der Saag P.T., de Laat S.W., den Hertog J.;
RT   "Cell scattering of SK-N-MC neuroepithelioma cells in response to Ret
RT   and FGF receptor tyrosine kinase activation is correlated with
RT   sustained ERK2 activation.";
RL   Oncogene 14:1147-1157(1997).
RX   PubMed=11668190; DOI=10.1177/002215540104901105;
RA   Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.;
RT   "Immunocytochemical analysis of cell lines derived from solid
RT   tumors.";
RL   J. Histochem. Cytochem. 49:1369-1378(2001).
RX   PubMed=15390183; DOI=10.1002/gcc.20096;
RA   Gebauer S., Yu A.L.-T., Omura-Minamisawa M., Batova A., Diccianni M.B.;
RT   "Expression profiles and clinical relationships of ID2, CDKN1B, and
RT   CDKN2A in primary neuroblastoma.";
RL   Genes Chromosomes Cancer 41:297-308(2004).
RX   PubMed=18160777; DOI=10.1159/000109614;
RA   Savola S., Nardi F., Scotlandi K., Picci P., Knuutila S.;
RT   "Microdeletions in 9p21.3 induce false negative results in CDKN2A FISH
RT   analysis of Ewing sarcoma.";
RL   Cytogenet. Genome Res. 119:21-26(2007).
RX   PubMed=19787792; DOI=10.1002/gcc.20717;
RA   Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S.,
RA   Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H.,
RA   Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W.,
RA   Buerger H., Aigner T., Gabbert H.E., Poremba C.;
RT   "Molecular characterization of commonly used cell lines for bone tumor
RT   research: a trans-European EuroBoNet effort.";
RL   Genes Chromosomes Cancer 49:40-51(2010).
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
RX   PubMed=23325432; DOI=10.1101/gr.147942.112;
RA   Varley K.E., Gertz J., Bowling K.M., Parker S.L., Reddy T.E.,
RA   Pauli-Behn F., Cross M.K., Williams B.A., Stamatoyannopoulos J.A.,
RA   Crawford G.E., Absher D.M., Wold B.J., Myers R.M.;
RT   "Dynamic DNA methylation across diverse human cell lines and
RT   tissues.";
RL   Genome Res. 23:555-567(2013).
RX   PubMed=24312454; DOI=10.1371/journal.pone.0080060;
RA   May W.A., Grigoryan R.S., Keshelava N., Cabral D.J., Christensen L.L.,
RA   Jenabi J., Ji L.-Y., Triche T.J., Lawlor E.R., Reynolds C.P.;
RT   "Characterization and drug resistance patterns of Ewing's sarcoma
RT   family tumor cell lines.";
RL   PLoS ONE 8:E80060-E80060(2013).
RX   PubMed=25010205; DOI=10.1371/journal.pgen.1004475;
RA   Brohl A.S., Solomon D.A., Chang W., Wang J.-J., Song Y., Sindiri S.,
RA   Patidar R., Hurd L., Chen L., Shern J.F., Liao H.-L., Wen X.-Y.,
RA   Gerard J., Kim J.-S., Lopez Guerrero J.A., Machado I., Wai D.H.,
RA   Picci P., Triche T.J., Horvai A.E., Miettinen M., Wei J.S.,
RA   Catchpoole D., Llombart-Bosch A., Waldman T., Khan J.;
RT   "The genomic landscape of the Ewing sarcoma family of tumors reveals
RT   recurrent STAG2 mutation.";
RL   PLoS Genet. 10:E1004475-E1004475(2014).
RX   PubMed=25223734; DOI=10.1158/2159-8290.CD-14-0622;
RA   Tirode F., Surdez D., Ma X.-T., Parker M., Le Deley M.-C., Bahrami A.,
RA   Zhang Z.-J., Lapouble E., Grossetete-Lalami S., Rusch M., Reynaud S.,
RA   Rio-Frio T., Hedlund E., Wu G., Chen X., Pierron G., Oberlin O.,
RA   Zaidi S., Lemmon G., Gupta P., Vadodaria B., Easton J., Gut M.,
RA   Ding L., Mardis E.R., Wilson R.K., Shurtleff S., Laurence V.,
RA   Michon J., Marec-Berard P., Gut I.G., Downing J., Dyer M., Zhang J.-H.,
RA   Delattre O.;
RT   "Genomic landscape of Ewing sarcoma defines an aggressive subtype with
RT   co-association of STAG2 and TP53 mutations.";
RL   Cancer Discov. 4:1342-1353(2014).
RX   PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074;
RA   Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E.,
RA   Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J.,
RA   Harris E., Monks A., Morris J.;
RT   "Sarcoma cell line screen of oncology drugs and investigational agents
RT   identifies patterns associated with gene and microRNA expression.";
RL   Mol. Cancer Ther. 14:2452-2462(2015).
RX   PubMed=26428435; DOI=10.1016/j.ejca.2015.08.020;
RA   Sand L.G.L., Scotlandi K., Berghuis D., Snaar-Jagalska B.E., Picci P.,
RA   Schmidt T., Szuhai K., Hogendoorn P.C.W.;
RT   "CXCL14, CXCR7 expression and CXCR4 splice variant ratio associate
RT   with survival and metastases in Ewing sarcoma patients.";
RL   Eur. J. Cancer 51:2624-2633(2015).
RX   PubMed=30879952; DOI=10.1016/j.ymthe.2019.02.014;
RA   Kailayangiri S., Altvater B., Lesch S., Balbach S.T., Gottlich C.,
RA   Kuhnemundt J., Mikesch J.-H., Schelhaas S., Jamitzky S., Meltzer J.,
RA   Farwick N., Greune L., Fluegge M., Kerl K., Lode H.N., Siebert N.,
RA   Muller I., Walles H., Hartmann W., Rossig C.;
RT   "EZH2 inhibition in Ewing sarcoma upregulates GD2 expression for
RT   targeting with gene-modified T cells.";
RL   Mol. Ther. 27:933-946(2019).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).